It is well known that the serum concentration of 1, 5-anhydroglucitiol (AG) decreases in diabetic patients. In this study, we evaluated the usefulness of AG measurement as a marker of glycemic control in diabetic patients with “near-normal” hyperglycemia (“near-normal” patients)(5.5≤HbA
1c≤6.5%). We also examined the serum AG concentration in newly diagnosed diabetic patients (HbA
1c>9.0%), patients with fair glycemic control (6.5<HbA
1c<7.5%), patients with impaired glucose tolerane (IGT) and normal subjects.
The mean serum AG concentration in “near-normal” patients was 15.2±6.9μg/m
l (mean±SD), which was significantly higher than in newly diagnosed patients (2.0±1.6) and patients with fair glycemic control (5.9±1.9), and definitely lower than in IGT (22.0±6.9) and normal subjects (24.3±7.9). However, the range of AG concentration in “near-normal” patients was wider (4.1-27μg/m
l) than in the other 4 groups.
We divided “near-normal” patients into two groups according to AG concentration (AG<10μg/m
l, AG≥10μg/m
l). There were no differences in the levels of HbA1c or postprandial blood glucose (2-hour) in the two groups.When the oral glucose tolerance test was performed in some of “near-normal” patients, while 10 of the 14 patients with high AG concentrations had IGT, no patients with low AG concentrations had IGT. We concluded that AG concentrations in “near-normal” patients may reflect finer glycemic control or immediate changes in blood glucose as a result of daily diet, in which there is no change in HbA
1c.
View full abstract